Lallemand Health Solutions' documented probiotic combination of Lactobacillus helveticus Rosell-52 and Bifidobacterium longum
The claims approved by ANVISA, the regulatory agency for health products in Brazil, are:
- “Lactobacillus helveticus R0052 and Bifidobacterium longum R0175 may contribute to the reduction of feelings of anxiety in healthy individuals”
- “Lactobacillus helveticus R0052 and Bifidobacterium longum R0175 contribute to the reduction of gastrointestinal complications such as abdominal pain and nausea/vomit brought on by light to moderate stress in healthy individuals.”
This approval follows the approval of similar claims by Health Canada’s NNHPD.
Solange Henoud, Global Regulatory Affairs Director for Lallemand Health Solutions, commented: “First, I would like to congratulate the team, given ANVISA’s rigourous requirements, receiving this approval was a huge accomplishment and success. It leaves us even more proud by being the first probiotic to be granted a specific health claim in Brazil since the regulation governing probiotics as functional foods/supplements has undergone modernisation for several years. The Rosell-52 and Rosell-175 probiotic combination was the first and still is the only probiotic to be formally approved by authorities in the Brain-Gut Axis area. Beyond Brazil’s rapidly growing supplement market, this recognition from competent authorities, Canada and now Brazil, adds value and indicates that the scientific evidence behind the product is reliable and verifiable."
Lallemand Health Solutions' Lacidofil and L. rhamnosus Rosell-11 have also been approved in Brazil.
